The funders that bankrolled a securities class action against collapsed engineering firm RCR Tomlinson will ask the court to give them an $8 million cut of a $40 million settlement. A further $12 million in legal fees means shareholders will get 50 per cent of the settlement sum.
A now-banned financial adviser has been hit with two charges of providing misleading information to the corporate regulator during a compulsory examination.
A judge has awarded carriage of a class action against Toyota unit Hino to Maurice Blackburn, finding that the law firm’s experience and resources trumped those of small personal injury firm Gerard Malouf & Partners, despite its alliance with a large US firm.
A judge has signed off on a class action settlement under which the Commonwealth Bank of Australia will pay a sum towards the applicant’s costs but group members will recover nothing.
Network Ten journalist Lisa Wilkinson has been accused of bias towards former defence minister Linda Reynolds because of a message she sent hours before an episode of The Project aired in which Brittany Higgins alleged she was raped in Parliament House, in which she said the senator was “lying through her teeth”.
Bruce Lehrmann will not call Brittany Higgins back to the witness box in his defamation trial against Network Ten and journalist Lisa Wilksinon to give evidence on a secret recording of a conversation between her fiancé and solicitor.
Honda Australia has been hit with a $6 million penalty for misleading communications made to customers of three dealerships during a restructuring in which the car maker’s shuttered its independent dealer network in favour of an agency model.
An investor class action against Virgin Australia has mounted a new challenge to a contentious indemnity clause, which the airline claims entitles it to receive periodic payments for its legal costs in defending the claims.
Despite proposing a divestiture as part of its planned takeover of Healius, Australian Clinical Labs has failed to win the approval of the competition regulator for the $1.5 billion deal.
The corporate regulator has brought proceedings against EverBlu Capital and Creso Pharma director Adam Blumenthal, alleging market rigging and breaches of duty, and has accepted an undertaking by the stockbroker that he will quit his involvement in financial services for the next five years.
For information on rights and reprints, contact subscriptions@lawyerly.com.au
